News | February 06, 2021
GlaxoSmithKline Pharmaceuticals Q3FY21 consolidated PAT at Rs. 156.51 Cr
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.
The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
State-of-the-art facility brings next-generation imaging and minimally invasive neurointerventional capabilities to Eastern India
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Backs Lifesigns in first bet and doubles down on India’s healthcare AI surge
Over 28 crore people screened, TB incidence falls sharply as Centre urges states to intensify efforts ahead of July campaign deadline
New facility equipped with advanced imaging technology to support 200 additional procedures a month and benefit nearly 3,000 more patients annually
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
